Endolaser for treating rosacea: Case report

International Journal of Development Research

Volume: 
13
Article ID: 
26904
4 pages
Research Article

Endolaser for treating rosacea: Case report

Fábio dos Santos Borges, Angelita Cristiane Ramos de Moura and Alessandro Oliveira de Moura

Abstract: 

Introduction: Rosacea is a chronic inflammatory skin disease characterized by persistent facial redness, telangiectasias, papules/pustules and skin lesions. Endolaser technique (also known as Endolift) uses a laser beam with a wavelength of 980 or 1470nm emitted through an optical fiber inserted into the subcutaneous tissue in order to tone the skin through neocollagenesis and/or reduce subcutaneous fat. Objective: This study aimed to report three cases of rosacea treatment using the endolaser with a wavelength of 980 nm. Methodology: Three cases of rosacea affecting the face of women who used the endolaser as the main treatment resource were reported. The procedure consisted of the application of a laser emitted through a 600 micron fiber optic, directed subdermally to treat dilated blood vessels and reduce the inflammation associated with rosacea. Each patient received a single treatment session. Results: In the reported cases, patients initially reassessed 30 days after the procedure, it was found a satisfactory decrease in rosacea, and free of intercurrences or complications. In the final reassessment, 8 weeks after the procedure, it was confirmed that there was no recurrence of the condition in this period and the final result remained extremely satisfactory. Conclusion: Finally, it is possible to conclude that the endolaser technique is effective for treating rosacea, showing itself as an innovative procedure, once through its photothermal action it has a great power of anti-inflammatory action, strongly contributing to the remission of clinical condition, and can also be associated with other therapeutic resources when there is another joint condition.

DOI: 
https://doi.org/10.37118/ijdr.26904.06.2023
Download PDF: